Table 5.
Most frequently reported adverse events (in ≥ 5% of patients in any treatment group). Patients administered C.E.R.A. QW or Q3W.
| C.E.R.A. dose group (μg/kg QW) | C.E.R.A. dose group (μg/kg Q3W) | |||||
| Adverse event, n (%) | 0.7 (n = 36) | 1.4 (n = 37) | 2.1 (n = 35) | 2.1 (n = 34) | 4.2 (n = 37) | 6.3 (n = 34) |
| Nausea | 12 (33) | 6 (16) | 11 (31) | 11 (32) | 7 (19) | 4 (12) |
| Fatigue | 11 (31) | 8 (22) | 7 (20) | 6 (18) | 10 (27) | 7 (21) |
| Anorexia | 7 (19) | 7 (19) | 7 (20) | 6 (18) | 7 (19) | 6 (18) |
| Vomiting | 8 (22) | 7 (19) | 9 (26) | 6 (18) | 2 (5) | 6 (18) |
| Neutropenia | 9 (25) | 3 (8) | 6 (17) | 8 (24) | 7 (19) | 4 (12) |
| Asthenia | 5 (14) | 5 (14) | 5 (14) | 6 (18) | 5 (14) | 4 (12) |
| Cough | 8 (22) | 3 (8) | 3 (9) | 5 (15) | 4 (11) | 4 (12) |
| Diarrhea | 6 (17) | 5 (14) | 4 (11) | 3 (9) | 6 (16) | 3 (9) |
C.E.R.A.: Continuous Erythropoietin Receptor Activator.
QW: once weekly.
Q3W: once every 3 weeks.